3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Venous Thromboembolism
10
Pulmonary Embolism
4
Venous Thrombosis
3
Neoplasms
3
Thrombosis
2
Multiple Myeloma
2
Urinary Bladder Neoplasms
1
Thromboprophylaxis
1
Thromboembolism
1
Thrombocytopenia
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Embolism
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Interventions
Temozolomide
100
Radiotherapy
49
Magnetic Resonance Spectroscopy
38
Radiation
28
Specimen Handling
25
pembrolizumab
22
Bevacizumab
22
Lomustine
16
Nivolumab
14
Surgical Procedures, Operative
10
atezolizumab
8
Cyclophosphamide
8
Biopsy
8
abemaciclib
7
Ipilimumab
7
fludarabine
6
Radiotherapy, Intensity-Modulated
6
Carboplatin
6
Aminolevulinic Acid
6
olaparib
5
Metformin
5
Drug Therapy
5
Diet, Ketogenic
5
Dianhydrogalactitol
5
poly ICLC
4
cemiplimab
4
Radiosurgery
4
Photons
4
Leukapheresis
4
Immunoglobulin G
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioblastoma
×
apixaban
×
1 year
×
Clear all
NCT05683808
2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2
Recruiting
40 enrolled